Business
Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development
Helix, the leading enterprise genomics company, today announced a multi-year relationship with Alnylam, the leading RNAi therapeutics company. This agreement provides Alnylam access to Helix's continuously growing, deeply phenotyped GenoSphere™ cohorts that cover a wide range of disease areas.
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"SAN MATEO, Calif., March 5, 2026 /PRNewswire/ -- Helix, the leading enterprise genomics company, today announced a multi-year relationship with Alnylam, the leading RNAi therapeutics company. This agreement provides Alnylam access to Helix's continuously growing, deeply phenotyped GenoSphere™ cohorts that cover a wide range of disease areas.","length":347,"tagName":"p"},{"type":"image","alt":"Helix (PRNewsfoto/Helix Inc)","displaySize":"","headline":null,"caption":"Helix (PRNewsfoto/Helix Inc)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":96,"url":"https://media.zenfs.com/en/prnewswire.com/4b1e8c7bae79d4d3228584a3d9777c1c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/95oy24WhwklQbr_swsnabQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/4b1e8c7bae79d4d3228584a3d9777c1c","width":400,"height":96}},"href":"https://mma.prnewswire.com/media/1397195/Helix_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Helix GenoSphere™ cohorts consist of comprehensive Exome+® genomic and rich longitudinal clinical data, enhanced with medical and pharmacy claims. Designed to accelerate Life Sciences research across the development cycle, these de-identified datasets are powered by Helix Research Network®, the largest and fastest growing precision health network in the world.","length":362,"tagName":"p"},{"type":"text","content":""We believe that access to the Helix platform will bolster our efforts to identify new targets for RNAi therapeutics, an innovative class of medicines that silence genes that cause or contribute to disease," says Paul Nioi, SVP, Research at Alnylam Pharmaceuticals. "We use human genetics to guide our drug discovery efforts, and we look forward to accessing the Helix platform, which includes data from genetically diverse patients across North America."","length":475,"tagName":"p"},{"type":"text","content":"Key advantages of Helix's datasets and network:","length":51,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Genomic data from Exome+® sequencing provides deep insights into thousands of genes and variants across a wide range of disease areas.","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"Curated, longitudinal clinical data with an averag...